Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence

David D. Kim, David W. Hutton, Ahmed A. Raouf, Mohsen Salama, Ahmed Hablas, Ibrahim A. Seifeldin, Amr S. Soliman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection is a major cause of cirrhosis and liver cancer, and many developing countries report intermediate-to-high prevalence. However, the economic impact of screening and treatment for HCV in high prevalence countries has not been well studied. Thus, we examined the cost-effectiveness of screening and treatment for HCV infection for asymptomatic, average-risk adults using a Markov decision analytic model. In our model, we collected age-specific prevalence, disease progression rates for Egyptians and local cost estimates in Egypt, which has the highest prevalence of HCV infection (~15%) in the world. We estimated the incremental cost-effectiveness ratio and conducted sensitivity analyses to determine how cost-effective HCV screening and treatment might be in other developing countries with high and intermediate prevalence. In Egypt, implementing a screening programme using triple-therapy treatment (sofosbuvir with pegylated interferon and ribavirin) was dominant compared with no screening because it would have lower total costs and improve health outcomes. HCV screening and treatment would also be cost-effective in global settings with intermediate costs of drug treatment (~$8000) and a higher sustained viral response rate (70–80%).

Original languageEnglish (US)
Pages (from-to)296-317
Number of pages22
JournalGlobal Public Health
Volume10
Issue number3
DOIs
StatePublished - Mar 16 2015

Fingerprint

Egypt
Hepatitis C
Hepacivirus
Cost-Benefit Analysis
Virus Diseases
Costs and Cost Analysis
Health Care Costs
Developing Countries
Drug Costs
Ribavirin
Liver Neoplasms
Interferons
Disease Progression
Fibrosis
Economics

Keywords

  • Egypt
  • cost-effectiveness
  • hepatitis C
  • screening
  • treatment

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Cost-effectiveness model for hepatitis C screening and treatment : Implications for Egypt and other countries with high prevalence. / Kim, David D.; Hutton, David W.; Raouf, Ahmed A.; Salama, Mohsen; Hablas, Ahmed; Seifeldin, Ibrahim A.; Soliman, Amr S.

In: Global Public Health, Vol. 10, No. 3, 16.03.2015, p. 296-317.

Research output: Contribution to journalArticle

Kim, David D. ; Hutton, David W. ; Raouf, Ahmed A. ; Salama, Mohsen ; Hablas, Ahmed ; Seifeldin, Ibrahim A. ; Soliman, Amr S. / Cost-effectiveness model for hepatitis C screening and treatment : Implications for Egypt and other countries with high prevalence. In: Global Public Health. 2015 ; Vol. 10, No. 3. pp. 296-317.
@article{8538d7986c4d452eb014ab7f7dbdad3a,
title = "Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence",
abstract = "Hepatitis C virus (HCV) infection is a major cause of cirrhosis and liver cancer, and many developing countries report intermediate-to-high prevalence. However, the economic impact of screening and treatment for HCV in high prevalence countries has not been well studied. Thus, we examined the cost-effectiveness of screening and treatment for HCV infection for asymptomatic, average-risk adults using a Markov decision analytic model. In our model, we collected age-specific prevalence, disease progression rates for Egyptians and local cost estimates in Egypt, which has the highest prevalence of HCV infection (~15{\%}) in the world. We estimated the incremental cost-effectiveness ratio and conducted sensitivity analyses to determine how cost-effective HCV screening and treatment might be in other developing countries with high and intermediate prevalence. In Egypt, implementing a screening programme using triple-therapy treatment (sofosbuvir with pegylated interferon and ribavirin) was dominant compared with no screening because it would have lower total costs and improve health outcomes. HCV screening and treatment would also be cost-effective in global settings with intermediate costs of drug treatment (~$8000) and a higher sustained viral response rate (70–80{\%}).",
keywords = "Egypt, cost-effectiveness, hepatitis C, screening, treatment",
author = "Kim, {David D.} and Hutton, {David W.} and Raouf, {Ahmed A.} and Mohsen Salama and Ahmed Hablas and Seifeldin, {Ibrahim A.} and Soliman, {Amr S.}",
year = "2015",
month = "3",
day = "16",
doi = "10.1080/17441692.2014.984742",
language = "English (US)",
volume = "10",
pages = "296--317",
journal = "Global Public Health",
issn = "1744-1692",
publisher = "Routledge",
number = "3",

}

TY - JOUR

T1 - Cost-effectiveness model for hepatitis C screening and treatment

T2 - Implications for Egypt and other countries with high prevalence

AU - Kim, David D.

AU - Hutton, David W.

AU - Raouf, Ahmed A.

AU - Salama, Mohsen

AU - Hablas, Ahmed

AU - Seifeldin, Ibrahim A.

AU - Soliman, Amr S.

PY - 2015/3/16

Y1 - 2015/3/16

N2 - Hepatitis C virus (HCV) infection is a major cause of cirrhosis and liver cancer, and many developing countries report intermediate-to-high prevalence. However, the economic impact of screening and treatment for HCV in high prevalence countries has not been well studied. Thus, we examined the cost-effectiveness of screening and treatment for HCV infection for asymptomatic, average-risk adults using a Markov decision analytic model. In our model, we collected age-specific prevalence, disease progression rates for Egyptians and local cost estimates in Egypt, which has the highest prevalence of HCV infection (~15%) in the world. We estimated the incremental cost-effectiveness ratio and conducted sensitivity analyses to determine how cost-effective HCV screening and treatment might be in other developing countries with high and intermediate prevalence. In Egypt, implementing a screening programme using triple-therapy treatment (sofosbuvir with pegylated interferon and ribavirin) was dominant compared with no screening because it would have lower total costs and improve health outcomes. HCV screening and treatment would also be cost-effective in global settings with intermediate costs of drug treatment (~$8000) and a higher sustained viral response rate (70–80%).

AB - Hepatitis C virus (HCV) infection is a major cause of cirrhosis and liver cancer, and many developing countries report intermediate-to-high prevalence. However, the economic impact of screening and treatment for HCV in high prevalence countries has not been well studied. Thus, we examined the cost-effectiveness of screening and treatment for HCV infection for asymptomatic, average-risk adults using a Markov decision analytic model. In our model, we collected age-specific prevalence, disease progression rates for Egyptians and local cost estimates in Egypt, which has the highest prevalence of HCV infection (~15%) in the world. We estimated the incremental cost-effectiveness ratio and conducted sensitivity analyses to determine how cost-effective HCV screening and treatment might be in other developing countries with high and intermediate prevalence. In Egypt, implementing a screening programme using triple-therapy treatment (sofosbuvir with pegylated interferon and ribavirin) was dominant compared with no screening because it would have lower total costs and improve health outcomes. HCV screening and treatment would also be cost-effective in global settings with intermediate costs of drug treatment (~$8000) and a higher sustained viral response rate (70–80%).

KW - Egypt

KW - cost-effectiveness

KW - hepatitis C

KW - screening

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84922451875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922451875&partnerID=8YFLogxK

U2 - 10.1080/17441692.2014.984742

DO - 10.1080/17441692.2014.984742

M3 - Article

C2 - 25469976

AN - SCOPUS:84922451875

VL - 10

SP - 296

EP - 317

JO - Global Public Health

JF - Global Public Health

SN - 1744-1692

IS - 3

ER -